InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,841.92
(
-0.31%
)
US TECH 100
19,669.20
(
-1.16%
)
Dow Jones
42,982.55
(
-0.19%
)
Brent Oil
73.52
(
-1.86%
)
Bitcoin
65,383.11
(
-1.04%
)
Post# of 58465
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

CAL_LAW

Send PM Follow Ignore
Followers 6
Posts 297
Boards Moderated 0
Alias Born 05/07/2001

CAL_LAW

Member Level

Re: None

Tuesday, 01/06/2004 2:53:42 PM

Tuesday, January 06, 2004 2:53:42 PM

Post# of 58465
RealCommentary from TheStreet.com
Genta Shares Should Be Therapeutic for Patient Investors
Tuesday January 6, 8:00 am ET

By Jonathan Moreland, Special to RealMoney.com

Longtime subscribers may recall my previous involvement with Genta (NasdaqNM:GNTA - News), a biotech with a promising new drug.

I bagged a 63.4% gain in less than a few months when I recommended the stock in late 2001. I suggested buying the stock once again in the summer of 2002 but lost about 4% when I was shaken out. Since then, the company has inched closer to final approval by the Food and Drug Administration, and shares have bounced in and out of favor. From a low of $5.50 this spring, Genta more than tripled to a recent high of $17.65.



"Never offend people with style when you can offend them with substance." --Sam Brown

Live long and prosper

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up